thyronines has been researched along with Neurodegenerative-Diseases* in 2 studies
1 review(s) available for thyronines and Neurodegenerative-Diseases
Article | Year |
---|---|
3-Iodothyronamine and Derivatives: New Allies Against Metabolic Syndrome?
In the two decades since its discovery, a large body of evidence has amassed to highlight the potential of 3-iodothyronamine (T1AM) as an antiobesity drug, whose pleiotropic signaling actions profoundly impact energy metabolism. In the present review, we recapitulate the most relevant properties of T1AM, including its structural and functional relationship to thyroid hormone, its endogenous levels, molecular targets, as well as its genomic and non-genomic effects on metabolism elicited in experimental models after exogenous administration. The physiological and pathophysiological relevance of T1AM in the regulation of energy homeostasis and metabolism is also discussed, along with its potential therapeutic applications in metabolic disturbances. Finally, we examine a number of T1AM analogs that have been recently developed with the aim of designing novel pharmacological agents for the treatment of interlinked diseases, such as metabolic and neurodegenerative disorders, as well as additional synthetic tools that can be exploited to further explore T1AM-dependent mechanisms and the physiological roles of trace amine-associated receptor 1 (TAAR1)-mediated effects. Topics: Animals; Energy Metabolism; Humans; Metabolic Syndrome; Neurodegenerative Diseases; Receptors, G-Protein-Coupled; Thyronines | 2020 |
1 other study(ies) available for thyronines and Neurodegenerative-Diseases
Article | Year |
---|---|
Delivery of Thyronamines (TAMs) to the Brain: A Preliminary Study.
Recent reports highlighted the significant neuroprotective effects of thyronamines (TAMs), a class of endogenous thyroid hormone derivatives. In particular, 3-iodothyronamine (T1AM) has been shown to play a pleiotropic role in neurodegeneration by modulating energy metabolism and neurological functions in mice. However, the pharmacological response to T1AM might be influenced by tissue metabolism, which is known to convert T1AM into its catabolite 3-iodothyroacetic acid (TA1). Currently, several research groups are investigating the pharmacological effects of T1AM systemic administration in the search of novel therapeutic approaches for the treatment of interlinked pathologies, such as metabolic and neurodegenerative diseases (NDDs). A critical aspect in the development of new drugs for NDDs is to know their distribution in the brain, which is fundamentally related to their ability to cross the blood-brain barrier (BBB). To this end, in the present study we used the immortalized mouse brain endothelial cell line bEnd.3 to develop an in vitro model of BBB and evaluate T1AM and TA1 permeability. Both drugs, administered at 1 µM dose, were assayed by high-performance liquid chromatography coupled to mass spectrometry. Our results indicate that T1AM is able to efficiently cross the BBB, whereas TA1 is almost completely devoid of this property. Topics: Animals; Biological Transport; Blood-Brain Barrier; Brain; Cell Line; Cell Line, Tumor; Coculture Techniques; Endothelial Cells; Humans; Mice; Neurodegenerative Diseases; Neuroprotective Agents; Permeability; Thyronines | 2021 |